Suliman pivoted to investment banking about two decades ago, earning an MBA at Oxford University, then holding positions at Lehman Brothers and later Petkevich & Partners. A few years later, she embarked on a successful career as a biotech business development executive. At Gilead, Suliman held management roles of increasing responsibility between 2005 and 2010 and played a significant role in expanding the company into new therapeutic areas, notably HIV . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Shehnaaz Suliman, MD, MPhil, Discusses Targeted Respiratory Therapies on “Close to the Edge” appeared first on GEN – Genetic Engineering and Biotechnology News.
